Fiche du document
2020
- handle: 10670/1.63bmca
Cairn
Mots-clés
Epidiolex cannabinoid skin rash hypersensitivity reaction antiepileptics drug interaction CBD Epidiolex® (cannabidiol)Sujets proches
Integument (Skin) CutisCiter ce document
Jaysingh Singh et al., « Epidiolex-induced skin rash », Epileptic Disorders, ID : 10670/1.63bmca
Métriques
Partage / Export
Résumé
Epidiolex® (cannabidiol, aka CBD) is a recently approved FDA prescription drug for the treatment of epilepsy associated with Lennox-Gastaut and Dravet syndromes, and is increasingly used for treatment-resistant epilepsy. Rash was rarely reported in Epidiolex® clinical trial data. We report a case of Epidiolex®-related skin rash that developed in a delayed fashion in a 23-year-old female with medically refractory epilepsy. We also review the potential mechanism of Epidiolex®-related skin rash.